NCT04034290View on ClinicalTrials.gov

A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

July 31, 2020

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

GamFluVac

The drug is a vaccine that induces high-level immunity against influenza A viruses

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

"Federal state budgetary institution Main military clinical hospital named after academician N. N. Burdenko of the Ministry of Defence of the Russian Federation", Moscow

All Listed Sponsors
collaborator

Main military clinical hospital named after academician N. N. Burdenko

UNKNOWN

lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER

NCT04034290 - A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac | Biotech Hunter | Biotech Hunter